Application of Biomarkers in the Development of Drugs Intended for the Treatment of Osteoarthritis OARSI FDA Osteoarthritis Biomarkers Working Group

OBJECTIVE Osteoarthritis (OA) is a chronic and slowly progressive disease for which biomarkers may be able to provide a more rapid indication of therapeutic responses to therapy than is currently available; this could accelerate and facilitate OA drug discovery and development programs. The goal of this document is to provide a summary and guide to the application of in vitro (biochemical and other soluble) biomarkers in the development of drugs for OA and to outline and stimulate a research agenda that will further this goal. METHODS The Biomarkers Working Group representing experts in the field of OA biomarker research from both academia and industry developed this consensus document between 2007 and 2009 at the behest of the Osteoarthritis Research Society International Federal Drug Administration initiative (OARSI FDA initiative). RESULTS This document summarizes definitions and classification systems for biomarkers, the current outcome measures used in OA clinical trials, applications and potential utility of biomarkers for development of OA therapeutics, the current state of qualification of OA-related biomarkers, pathways for biomarker qualification, critical needs to advance the use of biomarkers for drug development, recommendations regarding practices and clinical trials, and a research agenda to advance the science of OA-related biomarkers. CONCLUSIONS Although many OA-related biomarkers are currently available they exist in various states of qualification and validation. The biomarkers that are likely to have the earliest beneficial impact on clinical trials fall into two general categories, those that will allow targeting of subjects most likely to either respond and/or progress (prognostic value) within a reasonable and manageable time frame for a clinical study (for instance within 1-2 years for an OA trial), and those that provide early feedback for preclinical decision-making and for trial organizers that a drug is having the desired biochemical effect. As in vitro biomarkers are increasingly investigated in the context of specific drug treatments, advances in the field can be expected that will lead to rapid expansion of the list of available biomarkers with increasing understanding of the molecular processes that they represent.

[1]  A. Poole,et al.  Early rheumatoid-like lesions in rabbits injected with foreign serum: relationship to localization of immune complexes in the lining tissues of joints and cellular content of synovial fluid. , 1978, International archives of allergy and applied immunology.

[2]  H. Roos,et al.  Synovial fluid concentrations of the C-propeptide of type II collagen correlate with body mass index in primary knee osteoarthritis , 1997, Annals of the rheumatic diseases.

[3]  A. Poole,et al.  The assessment of cartilage degradation in vivo: development of an immunoassay for the measurement in body fluids of type II collagen cleaved by collagenases. , 2004, Journal of immunological methods.

[4]  Farshid Guilak,et al.  Urea as a passive transport marker for arthritis biomarker studies. , 2002, Arthritis and rheumatism.

[5]  D. DeMets,et al.  Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.

[6]  H. Babich,et al.  Cytotoxicity of T-2 toxin and its metabolites determined with the neutral red cell viability assay , 1991, Applied and environmental microbiology.

[7]  T. Kepler,et al.  First Qualification Study of Serum Biomarkers as Indicators of Total Body Burden of Osteoarthritis , 2010, PloS one.

[8]  S. Clarke,et al.  Suggestion of nonlinear or phasic progression of knee osteoarthritis based on measurements of serum cartilage oligomeric matrix protein levels over five years. , 2004, Arthritis and rheumatism.

[9]  K. Brandt,et al.  Urinary TIINE concentrations in a randomized controlled trial of doxycycline in knee osteoarthritis: implications of the lack of association between TIINE levels and joint space narrowing. , 2007, Arthritis and rheumatism.

[10]  A. Reiner,et al.  Molecular changes in human osteoarthritic cartilage after 3 weeks of oral administration of BAY 12-9566, a matrix metalloproteinase inhibitor. , 2003, The Journal of rheumatology.

[11]  D. Rennie,et al.  Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative , 2003, BMJ : British Medical Journal.

[12]  L M Hinman,et al.  The drug diagnostic co-development concept paper Commentary from the 3rd FDA-DIA-PWG-PhRMA-BIO Pharmacogenomics Workshop , 2006, The Pharmacogenomics Journal.

[13]  K. Marshall,et al.  Blood-based biomarkers for detecting mild osteoarthritis in the human knee. , 2005, Osteoarthritis and cartilage.

[14]  J. Singer,et al.  Glucosamine sulfate and cartilage type II collagen degradation in patients with knee osteoarthritis: randomized discontinuation trial results employing biomarkers. , 2005, The Journal of rheumatology.

[15]  D. Heinegård,et al.  Molecular markers of processes in cartilage in joint disease. , 1991, British journal of rheumatology.

[16]  P. Qvist,et al.  Collagen type II C-telopeptide fragments as an index of cartilage degradation. , 2001, Bone.

[17]  Claus Christiansen,et al.  The disease modifying osteoarthritis drug (DMOAD): Is it in the horizon? , 2008, Pharmacological research.

[18]  T. Spector,et al.  Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. , 2006, Arthritis and rheumatism.

[19]  K. Brandt,et al.  Associations between joint space narrowing and molecular markers of collagen and proteoglycan turnover in patients with knee osteoarthritis. , 2006, The Journal of rheumatology.

[20]  M. Percival,et al.  The type II collagen fragments Helix-II and CTX-II reveal different enzymatic pathways of human cartilage collagen degradation. , 2008, Osteoarthritis and cartilage.

[21]  Claus Christiansen,et al.  Effects of ovariectomy and estrogen therapy on type II collagen degradation and structural integrity of articular cartilage in rats: implications of the time of initiation. , 2006, Arthritis and rheumatism.

[22]  R. Buck,et al.  Association between concentrations of urinary type II collagen neoepitope (uTIINE) and joint space narrowing in patients with knee osteoarthritis. , 2006, Osteoarthritis and cartilage.

[23]  K. Yoshida,et al.  Analysis of unsaturated disaccharides from glycosaminoglycuronan by high-performance liquid chromatography. , 1989, Analytical biochemistry.

[24]  B. Bresnihan,et al.  Early changes in serum type II collagen biomarkers predict radiographic progression at one year in inflammatory arthritis patients after biologic therapy. , 2007, Arthritis and rheumatism.

[25]  C. Bingham,et al.  A 2 yr longitudinal radiographic study examining the effect of a bisphosphonate (risedronate) upon subchondral bone loss in osteoarthritic knee patients. , 2006, Rheumatology.

[26]  M. Kruhøffer,et al.  Isolation of microarray-grade total RNA, microRNA, and DNA from a single PAXgene blood RNA tube. , 2007, The Journal of molecular diagnostics : JMD.

[27]  H. Soares,et al.  Method Validation and Measurement of Biomarkers in Nonclinical and Clinical Samples in Drug Development: A Conference Report , 2005, Pharmaceutical Research.

[28]  D. Reid,et al.  Clinical trials in rheumatoid arthritis and osteoarthritis , 2008 .

[29]  M. Nevitt,et al.  Reliability of new indices of radiographic osteoarthritis of the hand and hip and lumbar disc degeneration. , 1993, The Journal of rheumatology.

[30]  Federico M Goodsaid,et al.  Strategic paths for biomarker qualification. , 2008, Toxicology.

[31]  A. Jaffe,et al.  N-terminal pro-B-type natriuretic peptide concentrations predict the risk of cardiovascular adverse events from antiinflammatory drugs: a pilot trial. , 2008, Clinical chemistry.

[32]  H. Hinghofer-Szalkay,et al.  Plasma hyaluronan concentration: no circadian rhythm but large effect of food intake in humans , 1998, European Journal of Applied Physiology and Occupational Physiology.

[33]  Jh. Kellgren.  Radiological assessment of osteoarthrosis , 1957 .

[34]  P. Tugwell,et al.  Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III. , 1997, The Journal of rheumatology.

[35]  P. Garnero,et al.  PIIANP and HELIXII diurnal variation. , 2008, Osteoarthritis and cartilage.

[36]  T. Spector,et al.  Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173] , 2005, Arthritis research & therapy.

[37]  D J Hunter,et al.  Classification of osteoarthritis biomarkers: a proposed approach. , 2006, Osteoarthritis and cartilage.

[38]  O. Nemirovskiy,et al.  Discovery and development of a type II collagen neoepitope (TIINE) biomarker for matrix metalloproteinase activity: from in vitro to in vivo. , 2007, Analytical biochemistry.

[39]  R. Coleman,et al.  Whole-body bone scintigraphy provides a measure of the total-body burden of osteoarthritis for the purpose of systemic biomarker validation. , 2009, Arthritis and rheumatism.

[40]  J. Houwing-Duistermaat,et al.  Urinary CTX-II levels are associated with radiographic subtypes of osteoarthritis in hip, knee, hand, and facet joints in subject with familial osteoarthritis at multiple sites: the GARP study , 2005, Annals of the rheumatic diseases.

[41]  P. Delmas,et al.  Biological markers in osteoarthritis , 2007, Nature Clinical Practice Rheumatology.

[42]  J. Wagner,et al.  Biomarkers and Surrogate End Points for Fit‐for‐Purpose Development and Regulatory Evaluation of New Drugs , 2007, Clinical pharmacology and therapeutics.

[43]  A. Milewicz,et al.  Feasibility of simultaneous measurement of bone formation and bone resorption markers to assess bone turnover rate in postmenopausal women: an EPOLOS study. , 2008, Medical science monitor : international medical journal of experimental and clinical research.

[44]  B. Mazières,et al.  Effect of chondroitin sulphate in symptomatic knee osteoarthritis: a multicentre, randomised, double-blind, placebo-controlled study , 2007, Annals of the rheumatic diseases.

[45]  D. Uebelhart,et al.  Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease. , 1990, Bone and mineral.

[46]  Alan Brett,et al.  Trabecular morphometry by fractal signature analysis is a novel marker of osteoarthritis progression. , 2009, Arthritis and rheumatism.

[47]  J. Singer,et al.  Association of biomarkers with pre-radiographically defined and radiographically defined knee osteoarthritis in a population-based study. , 2009, Arthritis and rheumatism.

[48]  A. Cole,et al.  Differential matrix degradation and turnover in early cartilage lesions of human knee and ankle joints. , 2005, Arthritis and rheumatism.

[49]  S. Christgau.  Circadian variation in serum CrossLaps concentration is reduced in fasting individuals. , 2000, Clinical chemistry.

[50]  W. Murphy,et al.  The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand. , 1990, Arthritis and rheumatism.

[51]  E. Losina,et al.  Joint space narrowing and Kellgren-Lawrence progression in knee osteoarthritis: an analytic literature synthesis. , 2008, Osteoarthritis and cartilage.

[52]  A. Poole,et al.  Studies of the articular cartilage proteoglycan aggrecan in health and osteoarthritis. Evidence for molecular heterogeneity and extensive molecular changes in disease. , 1992, The Journal of clinical investigation.

[53]  J. Tanus-Santos,et al.  Effect of anticoagulants on the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. , 2005, Analytical biochemistry.

[54]  S. Majumdar,et al.  A study of the relationship between molecular biomarkers of joint degeneration and the magnetic resonance-measured characteristics of cartilage in 16 symptomatic knees. , 2004, Magnetic resonance imaging.

[55]  C. Helmick,et al.  Ethnic and sex differences in serum levels of cartilage oligomeric matrix protein: the Johnston County Osteoarthritis Project. , 2003, Arthritis and rheumatism.

[56]  L. Lesko,et al.  Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. , 2001, Annual review of pharmacology and toxicology.

[57]  Federico Goodsaid,et al.  Process map proposal for the validation of genomic biomarkers. , 2006, Pharmacogenomics.

[58]  Leonard Steinborn,et al.  The United States Code of Federal Regulations 21 CFR, Part 211, Current Good Manufacturing Practice for Finished Pharmaceuticals , 2004 .

[59]  P. Tugwell,et al.  Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema. , 2007, The Journal of rheumatology.

[60]  A. Sudo,et al.  Changes in biochemical markers and prediction of effectiveness of intra-articular hyaluronan in patients with knee osteoarthritis. , 2008, Osteoarthritis and cartilage.

[61]  Y. Henrotin,et al.  Collagen fibril disruption occurs early in primary guinea pig knee osteoarthritis. , 2010, Osteoarthritis and cartilage.

[62]  C. Christiansen,et al.  Association between spine disc degeneration and type II collagen degradation in postmenopausal women: the OFELY study. , 2004, Arthritis and rheumatism.

[63]  M. Hanes,et al.  A comparative analysis of bone and cartilage metabolism in two strains of guinea-pig with varying degrees of naturally occurring osteoarthritis. , 2002, Osteoarthritis and cartilage.

[64]  H. Mischak,et al.  Quantitative urinary proteome analysis for biomarker evaluation in chronic kidney disease. , 2009, Journal of proteome research.

[65]  F. Eckstein,et al.  One year change of knee cartilage morphology in the first release of participants from the Osteoarthritis Initiative progression subcohort: association with sex, body mass index, symptoms and radiographic osteoarthritis status , 2008, Annals of the rheumatic diseases.

[66]  D. Eyre,et al.  Biochemical Markers as Surrogate End Points of Joint Disease , 2008 .

[67]  J. Jordan,et al.  Diurnal variation of serum and urine biomarkers in patients with radiographic knee osteoarthritis. , 2006, Arthritis and rheumatism.

[68]  P. Garnero,et al.  Monitoring cartilage turnover , 2007, Current rheumatology reports.

[69]  P. Dieppe,et al.  Evidence for altered synthesis of type II collagen in patients with osteoarthritis. , 1998, The Journal of clinical investigation.

[70]  C. Rorabeck,et al.  Increased damage to type II collagen in osteoarthritic articular cartilage detected by a new immunoassay. , 1994, The Journal of clinical investigation.

[71]  F. Guilak,et al.  Novel synovial fluid recovery method allows for quantification of a marker of arthritis in mice. , 2008, Osteoarthritis and Cartilage.

[72]  V. Kraus,et al.  Collagen Biomarkers for Arthritis Applications , 2006, Biomarker insights.

[73]  Table of Valid Genomic Biomarkers in the Context of Approved Drug Labels , 2009 .

[74]  Nils Brünner,et al.  Banking of Biological Fluids for Studies of Disease-associated Protein Biomarkers* , 2008, Molecular & Cellular Proteomics.

[75]  D. Eyre,et al.  Collagen cross-links as markers of bone and cartilage degradation , 2002 .

[76]  D. Eyre,et al.  The Helix-II epitope: a cautionary tale from a cartilage biomarker based on an invalid collagen sequence. , 2009, Osteoarthritis and cartilage.

[77]  E. Colman.  The Food and Drug Administration's Osteoporosis Guidance Document: Past, Present, and Future , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[78]  E. Thonar,et al.  Accumulation of hyaluronate in human lung carcinoma as measured by a new hyaluronate ELISA. , 1989, Connective tissue research.

[79]  Jean-Pierre Devogelaer,et al.  Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis. , 2004, Osteoarthritis and cartilage.

[80]  S. Miyauchi,et al.  Quantitation of chondroitin 4-sulfate and chondroitin 6-sulfate in pathologic joint fluid. , 1992, Arthritis and rheumatism.

[81]  W. Lems,et al.  Serum and urinary biochemical markers for knee and hip-osteoarthritis: a systematic review applying the consensus BIPED criteria. , 2010, Osteoarthritis and cartilage.

[82]  D. Heinegård,et al.  COMP Acts as a Catalyst in Collagen Fibrillogenesis* , 2007, Journal of Biological Chemistry.

[83]  H C Charles,et al.  Optimization of the fixed-flexion knee radiograph. , 2007, Osteoarthritis and cartilage.

[84]  C. Christiansen,et al.  Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the Knee Osteoarthritis Structural Arthritis randomized clinical trial. , 2008, Osteoarthritis and cartilage.

[85]  N. Bhardwaj,et al.  Detection of stromelysin and collagenase in synovial fluid from patients with rheumatoid arthritis and posttraumatic knee injury. , 1992, Arthritis and rheumatism.

[86]  K. Brandt,et al.  Urinary levels of type II collagen C-telopeptide crosslink are unrelated to joint space narrowing in patients with knee osteoarthritis , 2005, Annals of the rheumatic diseases.

[87]  Mads Nielsen,et al.  Identification of progressors in osteoarthritis by combining biochemical and MRI-based markers , 2009, Arthritis research & therapy.

[88]  P. Delmas,et al.  Urinary excretion of glucosyl-galactosyl pyridinoline: a specific biochemical marker of synovium degradation. , 2001, Rheumatology.

[89]  E. Thonar,et al.  Oral salmon calcitonin reduces Lequesne's algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis. , 2006, Arthritis and rheumatism.

[90]  M. Payton,et al.  Soy protein may alleviate osteoarthritis symptoms. , 2004, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[91]  D. Felson,et al.  Whither osteoarthritis biomarkers? , 2009, Osteoarthritis and cartilage.

[92]  J. Abraham.  The international conference on harmonisation of technical requirements for registration of pharmaceuticals for human use , 2009 .

[93]  P Kjaersgaard-Andersen,et al.  Biochemical markers of type II collagen breakdown and synthesis are positioned at specific sites in human osteoarthritic knee cartilage. , 2008, Osteoarthritis and cartilage.

[94]  R. Moskowitz,et al.  Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. , 1986, Arthritis and rheumatism.

[95]  M. Dougados,et al.  Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis. , 2002, Arthritis and rheumatism.

[96]  T D Cooke,et al.  The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. , 1991, Arthritis and rheumatism.

[97]  E. Thonar,et al.  Quantification of keratan sulfate in blood as a marker of cartilage catabolism. , 1985, The Journal of rheumatology.

[98]  T. Cawston,et al.  Markers of joint destruction: principles, problems, and potential , 2001, Annals of the rheumatic diseases.

[99]  Y. Henrotin,et al.  Type II collagen markers in osteoarthritis: what do they indicate? , 2007, Current opinion in rheumatology.

[100]  J. Reginster,et al.  Osteoarthritic patients with high cartilage turnover show increased responsiveness to the cartilage protecting effects of glucosamine sulphate. , 2004, Clinical and experimental rheumatology.

[101]  G. Embery,et al.  Modulation of Collagen Fibrillogenesis by Dentinal Proteoglycans , 2005, Calcified Tissue International.

[102]  E. Thonar,et al.  Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. , 1998, Osteoarthritis and cartilage.

[103]  E. Roos,et al.  Serum levels of Cartilage Oligomeric Matrix Protein (COMP) increase temporarily after physical exercise in patients with knee osteoarthritis , 2006, BMC musculoskeletal disorders.

[104]  P. Delmas,et al.  Effects of ibuprofen on molecular markers of cartilage and synovium turnover in patients with knee osteoarthritis , 2004, Annals of the rheumatic diseases.

[105]  J B Renner,et al.  Serum cartilage oligomeric matrix protein reflects osteoarthritis presence and severity: the Johnston County Osteoarthritis Project. , 1999, Arthritis and rheumatism.

[106]  Staffan Larsson,et al.  Use of the plasma stromelysin (matrix metalloproteinase 3) concentration to predict joint space narrowing in knee osteoarthritis. , 2005, Arthritis and rheumatism.

[107]  M. Karsdal,et al.  Biochemical markers and the FDA Critical Path: How biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development , 2009, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[108]  V. Kraus,et al.  Variation in osteoarthritis biomarkers from activity not food consumption. , 2008, Clinica chimica acta; international journal of clinical chemistry.

[109]  Y. Washimi,et al.  Content and sulfation pattern of keratan sulfate in hip osteoarthritis using high performance liquid chromatography. , 2000, The Journal of rheumatology.

[110]  L. Sharma,et al.  The ratio of type II collagen breakdown to synthesis and its relationship with the progression of knee osteoarthritis. , 2007, Osteoarthritis and cartilage.

[111]  V. Hascall,et al.  The Many Faces of Osteoarthritis , 2002, Birkhäuser Basel.

[112]  E. Thonar,et al.  Effect of an exercise and dietary intervention on serum biomarkers in overweight and obese adults with osteoarthritis of the knee. , 2008, Osteoarthritis and cartilage.

[113]  T. Spector,et al.  Kellgren & Lawrence grade 1 osteophytes in the knee--doubtful or definite? , 2003, Osteoarthritis and cartilage.

[114]  A Guermazi,et al.  Change in joint space width: hyaline articular cartilage loss or alteration in meniscus? , 2006, Arthritis and rheumatism.

[115]  C. Rorabeck,et al.  Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. , 1997, The Journal of clinical investigation.

[116]  V. Kraus,et al.  Assessment of the utility of biomarkers of osteoarthritis in the guinea pig. , 2006, Osteoarthritis and cartilage.

[117]  F. Frueh,et al.  Biomarker qualification pilot process at the US Food and Drug Administration , 2007, The AAPS Journal.

[118]  M. Dougados,et al.  OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. , 2004, Osteoarthritis and cartilage.

[119]  E. Vignon,et al.  Serum concentrations of type II collagen biomarkers (C2C, C1, 2C and CPII) suggest different pathophysiologies in patients with hip osteoarthritis. , 2008, Clinical and experimental rheumatology.

[120]  L. Ferrucci,et al.  Serum protein signatures detect early radiographic osteoarthritis. , 2009, Osteoarthritis and cartilage.

[121]  J. Kellgren,et al.  Radiological Assessment of Osteo-Arthrosis , 1957, Annals of the rheumatic diseases.